• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Intermittent vagal nerve block ineffective for weight loss in obesity

byMilana Bogorodskaya, MDandPriyanka Vedak
September 2, 2014
in Chronic Disease, Gastroenterology, Public Health
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In patients with morbid obesity, intermittent intra-abdominal vagal nerve blockade did not induce significant body weight loss (>20%) when compared to a placebo device.

2. While the safety profile of the device itself was low, adverse events associated with abdominal surgery and anesthesia persist.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: The vagus nerve interacts with the gastrointestinal track to influence dietary intake through multiple mechanisms. This study sought to provide an alternative to current bariatric surgeries for the treatment of morbid obesity. Results showed that while intermittent intra-abdominal vagal nerve blockade resulted in more weight loss than the placebo device, this weight loss did not meet the study’s predefined criteria for significant excess body weight loss (excess weight loss >20%) when compared to a placebo device.

The strengths of this study include the strict design with regards to the outlined efficacy and safety objectives, as well as the randomization and blinding utilized given the invasive nature of the investigated intervention. Limitations of the study include the small percentage of study participants with type II diabetes. Given the potential for associated confounding factors, it is understandable why the authors decided to limit the number of diabetic participants in the study. However, since a large percentage (>10%) of patients with morbid obesity have type II diabetes, this exclusion hinders the generalization of these results to the population at large. Keeping these limitations in mind, this study suggests that intermittent intra-abdominal vagal nerve block does not produce significantly superior results (>10% difference in weight loss from controls) when compared to placebo therapy.

Click to read the study, published today in JAMA

RELATED REPORTS

Once-monthly bofanglutide maintained weight loss over 24 weeks in topline phase 3 results

Prognostic associations of anthropometric indices vary by clinical outcomes

Click to read the accompanying editorial, published today in JAMA

Relevant Reading: Bariatric surgery versus non-surgical treatment for obesity: a systemic review and meta-analysis of randomised controlled trials

FDA approvedFor obesity: Foundayo (orforglipron), Apr 1, 2026→

In-Depth [randomized controlled trial]: This multicenter study enrolled 239 participants with a body max index (BMI) between 35-45 and at least one co-morbidity related to obesity, and randomized them to receive either an active vagal nerve block device or a placebo device. The primary objectives regarding device efficacy were to 1) assess the mean percent of excess weight loss between the two groups and 2) for 55% of patients in the experimental group to achieve 20% excess weight loss and for 45% to achieve at least 25% excess weight loss. Results showed that the mean percentage of excess weight loss was 24.4% in the active device group and 15.9% in the placebo device group, with a mean difference of 8.5% (95%CI, 3.1-13.9). Fifty-two percent of participants achieved the 20% excess weight loss mark, and only 38% achieved 25% excess weight loss. Consequently, neither of these two primary endpoints for device efficacy was achieved.

The primary objective regarding device safety was to demonstrate an adverse event rate of <15%. This objective was met, with only 3.7% of participants reporting an adverse event related to the device, and 8.6% of participants reporting an adverse event when adverse events related to surgery and anesthesia were included. The most common adverse effects related to the device were nausea, heartburn, and pain at the implantation site.

More from this author: The CLARITY trial: Adding clopidogrel to STEMI management [Classics Series], Aspirin vs warfarin in atherosclerotic intracranial stenosis [Classics Series], The ARISTOTLE trial: Apixaban vs warfarin in atrial fibrillation [Classics Series], The TRITON trial: Prasugrel vs clopidogrel in ACS [Classics Series], Vena caval filters in pulmonary embolism prophylaxis [Classics Series]

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: bariatric surgeryBMIobesity
Previous Post

Low-carb, not low-fat, diet linked with increased weight loss

Next Post

Higher sodium intake linked to more aggressive multiple sclerosis

RelatedReports

Obesity treatment collage: a bathroom scale with a blank dial, a coiled tape measure and a bowl of fresh vegetables
2MM Trial Briefs

Once-monthly bofanglutide maintained weight loss over 24 weeks in topline phase 3 results

November 5, 2026
An illustration featuring a heart within a house, with a stethoscope, a scale, and medication, symbolizing heart failure home hospital care.
Cardiology

Prognostic associations of anthropometric indices vary by clinical outcomes

September 28, 2026
Weight loss collage: a smiling bearded man in an open-collared shirt beside a coiled leather belt and a plate of salad greens
Endocrinology

Newer GLP-1 agents yield substantial weight loss in nondiabetic adults

August 31, 2026
Weight management collage: a smiling middle-aged woman in a collared blouse beside a pear, a mint sprig and a coiled belt
Chronic Disease

Sleep restriction promotes weight gain in high-risk adults 

July 6, 2026
Next Post

Higher sodium intake linked to more aggressive multiple sclerosis

No mortality benefit with bilateral mastectomy vs breast-conserving surgery

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Beta-blockers ineffective for treating combined heart failure and atrial fibrillation

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ivonescimab plus chemotherapy produced major and complete pathological responses in resectable NSCLC in a phase II study
  • Medicaid status, race and ethnicity are independently associated with increased odds of severe maternal morbidity
  • Artificial intelligence-generated pre-visit summaries improved communication outcomes in neurosurgical consultations
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.